FDC gets USFDA nod for Ofloxacin Otic Solution

Published On 2022-01-24 11:10 GMT   |   Update On 2022-01-25 05:14 GMT

Mumbai: Pharma firm FDC Limited has recently announced that the company has received approval from the United States Food and Drug Administration (USFDA) for Ofloxacin Otic Solution, 0.3%."This is to inform you that, the Company has been granted ANDA approval by USFDA, for Ofloxacin Otic Solution, 0.3%," the company said in a BSE filing.An abbreviated new drug application contains data which...

Login or Register to read the full article

Mumbai: Pharma firm FDC Limited has recently announced that the company has received approval from the United States Food and Drug Administration (USFDA) for Ofloxacin Otic Solution, 0.3%.

"This is to inform you that, the Company has been granted ANDA approval by USFDA, for Ofloxacin Otic Solution, 0.3%," the company said in a BSE filing.

An abbreviated new drug application contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.

Read also: Covid-19: FDC launches first Favipiravir Oral Suspension Favenza in India

Founded in 1936, FDC Limited is the pharmaceutical company headquartered in India.


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News